Phase 12a Study Evaluating MDX2001 Monotherapy for Advanced Solid Tumors
A Multicenter, Open-label Clinical Trial Assessing Safety and Anti-tumor Activity
Led by ModeX Therapeutics, An OPKO Health Company · Updated on 2026-10-15
330
Participants Needed
6
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating MDX2001 for safety, tolerability, and anti-tumor activity in patients with advanced solid tumors. This study includes Phase 1a dose escalation, Phase 1b dose expansion in a single tumor type, and Phase 2a expansion. The goal is to identify a recommended dose for Phase 2 and assess how MDX2001 works in selected tumors.
Participants receive MDX2001 either as an intravenous infusion or a subcutaneous injection. Treatment dosing and schedules vary across study phases, with patients in the expansion phases receiving the recommended Phase 2 dose. The studys duration per patient is expected to be around 10 months, including screening, treatment, and long-term follow-up.
During the trial, participants undergo safety monitoring, tumor assessments, and evaluations of MDX2001s effects on their cancer. Researchers collect data on adverse events, tumor response, pharmacokinetics, immunogenicity, and tumor protein expression. Follow-up continues for several months after treatment to observe ongoing outcomes and safety.
CONDITIONS
Brief Title
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Research Team
E
Email recommended
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
MDX2001 (investigational)
Current standard therapy
What it is
A tetraspecific Lymphocyte Activation and Survival Enhancement Receptor (LASER) antibody engaging CD3, CD28 on T cells and c-MET, TROP2 on tumor cells, delivered via intravenous or subcutaneous dosing in escalating and expansion cohorts.
Established therapies for advanced solid tumors vary by cancer type and may include targeted agents, chemotherapy, immunotherapy or combinations per current guidelines.
Role in trial
Investigational single-agent treatment evaluated through dose escalation and expansion phases without comparator arm.
Not part of the trial; represents treatment patients could receive instead of enrolling in the study.
Primary use
To establish safety, tolerability, recommended phase 2 dose, pharmacokinetics, immunogenicity and preliminary anti‑tumor activity in advanced solid tumors.
To control disease progression or reduce tumor burden using approved regimens tailored to each cancer type.
How it is given or performed
Administered as intravenous infusion or subcutaneous injection in sequential escalating and expansion cohorts.
Delivered according to each approved therapy’s standard route, schedule, and dosing per cancer type.
Evidence status
Evidence consists of preclinical and early dose‑escalation/expansion data; safety and anti‑tumor activity are under investigation.
Evidence is based on completed clinical trials and guideline‑recommended use in each cancer type.
Important risks
Potential for immune‑related or infusion‑related adverse events, tolerability and safety to be defined.
Risks vary by therapy but are generally well‑characterized in regulatory labels and clinical literature.
Important limitations
Limited early‑phase data in heterogeneous tumor types; no direct comparison arm; optimal dose and efficacy not yet confirmed.
Efficacy and safety vary by tumor type; some patients may not respond or may experience toxicity.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patients must be 18 years of age or older
Confirmed diagnosis of metastatic solid tumors by histology or cytology
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
At least one measurable tumor lesion per RECIST v1.1 criteria
Use of contraception consistent with local regulations for clinical study participants
Adequate blood, liver, and kidney function
Ability to provide signed informed consent
You will not qualify if you...
Any significant cardiac disease
Unresolved side effects from prior cancer treatments
Previous solid organ or blood stem cell transplant
Active, untreated, or uncontrolled brain metastases
Known HIV infection, active hepatitis B or C, or ongoing infection requiring IV treatment
Receipt of live-virus vaccination within 28 days before treatment
Any condition making participation unsuitable as judged by the investigator
Participation in another clinical study during treatment
Known allergy to MDX2001 or its ingredients
Use of supplemental oxygen for daily activities
Your Study Journey
Screening
Duration - Up to 1 month
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Median of 6 months
Participants receive MDX2001 as an intravenous infusion or subcutaneous injection with dosing adjusted through study phases to find the recommended dose and assess anti-tumor activity.
Visits scheduled according to treatment cycles
Long-term Follow-up
Duration - Median of 3 months
Participants are monitored for safety and tumor response after treatment ends to evaluate ongoing effects of MDX2001.
Periodic follow-up visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Safety and Dosimetry Study of 177Lu-RAD204 Targeting PD-L1 in Patients With Selected Metastatic Solid Tumors
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Phase I Study of 177Lu-CTR-FAPI Radioligand Therapy for Thyroid Cancer Evaluating Safety and Effectiveness
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Safety and Effectiveness of a New 18F Labeled Fibroblast Activation Protein Probe for Early Tumor Detection
Including Lung, Pancreatic, Neuroendocrine, and Thyroid Cancers
Using 18F-FAraG PETCT Scans to Detect Tumors and Predict Treatment Response in Esophageal Cancer Patients Undergoing Chemoradiation
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors.